{"disease":{"id":"capecitabine","name":"capecitabine"},"drugs":{"marketed":[{"drug_id":"ixabepilone","indication_name":"Metastatic or locally advanced breast cancer with capecitabine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06616259","title":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":452,"lead_sponsor_name":"Meng Qiu","has_results":false},{"nct_id":"NCT03500380","title":"A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":301,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT03889626","title":"The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":242,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06602167","title":"Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Affiliated Hospital of Qinghai University","has_results":false},{"nct_id":"NCT07063706","title":"Pharmaceutical Care for Patients Using Capecitabine","phase":"NA","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Faculdade de Farmácia","has_results":false},{"nct_id":"NCT07177560","title":"Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS)","phase":"","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Gazi University","has_results":false},{"nct_id":"NCT05022030","title":"First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06246461","title":"The Therapeutic Effect of Different Doses of Capecitabine","phase":"NA","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Jingjiang People's Hospital","has_results":false},{"nct_id":"NCT03079427","title":"Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT05940441","title":"A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Eye & ENT Hospital of Fudan University","has_results":false},{"nct_id":"NCT06188000","title":"Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Universitas Sriwijaya","has_results":false},{"nct_id":"NCT06202014","title":"Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":43,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03079440","title":"TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT06405490","title":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05290194","title":"Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Fifth Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04720131","title":"Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05841134","title":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}